Key points are not available for this paper at this time.
Poly(ADP-ribose) polymerase inhibitors (PARPis) improved advanced ovarian cancer treatment. Most patients progress during or following PARPi exposure, however, with concerns about sensitivity of subsequent chemotherapy.
Xu-Vuillard et al. (2024) studied this question.